Navigation Links
Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
Date:2/13/2009

    New manufacturing facility opening in Second Quarter

TORONTO, Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) said today that despite a challenging year for the biopharmaceutical industry, it has maintained its focus and continued its advance toward the ultimate goal of sustained profitability. The Company was announcing results for the first quarter ended December 31, 2008.

In a news release today, William J. Gastle, CEO of Microbix said "the Company has improved the fundamentals of its core business and we are approaching major milestones in our product pipeline. We are waiting for the FDA to authorize release of Kinlytic inventory, our Urokinase product, we are in discussions with potential pharma partners for our Hunan (China) influenza vaccine business and we expect to provide guidance on the SST program as we near the end of the expanded sex specific protein investigation described in 2008."

    First Quarter Highlights

    Core Business

Growth was robust in the first quarter with sales improving over 50 per cent compared to the same quarter last year. "We exceeded our sales target in the first quarter," Mr. Gastle continued "and we are on a path to meet or exceed projections for this fiscal year. The Company will open its new facility in Mississauga, Ontario in March 2009 with significantly improved capacity.

VIRUSMAX(TM)

The Company is collaborating with a major firm to evaluate VIRUSMAX in their influenza vaccine manufacturing process in the second quarter. Preliminary results were promising and the evaluation has moved to the next phase at the partner's manufacturing facility.

We are pleased with the arrangement to form a manufacturing joint venture agreement to build and operate an influenza vaccine plant in China based on VIRUSMAX. We are making solid progress towards completing the pre-conditions that hav
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
2. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
3. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
4. Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
5. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
6. Max Muscle Introduces First-Ever Probiotics Protein Bar
7. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
8. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
9. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
11. World's First Website for Patients to Share Diagnostic-Quality Medical Images
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... March 13 Innocoll, Inc., a,privately-held biopharmaceutical ... of planned phase 2 clinical trials sponsored ... to investigate CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the ... Innocoll,s BUPIVACAINE SURGICAL IMPLANT is a biodegradable ...
... scientists worldwide gain new insight ... funding support for human brain, spinal cord and developing ... brain projects, ... it is undertaking three major projects designed to,accelerate brain, and spinal cord research, ...
... 93.3%; Full Year Net Income up 283.0%, SHANGHAI, ... WX ), the leading global pharmaceutical,biotechnology and medical ... its unaudited financial results for the,fourth quarter and full ... 2007 Highlights:, Compared to the fourth quarter 2006 ...
Cached Biology Technology:Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 2Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 3Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 12
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... (WSU) Laboratory for Atmospheric Research is leading a nationwide ... the distribution of natural gas. Beginning this month, ... Lamb will quantify methane emissions throughout local gas systems ... data to estimate a national methane emissions rate for ...
... the University of Michigan have identified a new potential ... alternative or complementary therapy to statins. Scientists ... Sciences Institute inhibited the action of a gene responsible ... of the liver to remove cholesterol from the blood ...
... animals are frequently observed scavenging on other animals whether it ... or a buzzard swooping down on a dead animal. However, ... difficult, and often overlooked in marine food web studies. , ... titled, " White sharks ( Carcharodon carcharias ) scavenging on ...
Cached Biology News:Methane emissions from natural gas local distribution focus of new study 2Methane emissions from natural gas local distribution focus of new study 3U-M researchers find new way to clear cholesterol from the blood 2Great white sharks 2
... the popular precision current source, designed ... neural transport tracers such as horseradish ... into neural tissue, is now available ... used to make small lesions, and ...
... Thermostable dUTPase The thermostable ... high-fidelity PCR (using proofreading DNA polymerases). ... in PCR reactions and dNTP solutions. ... a proofreading DNA polymerase reaction can ...
... The FLUOstar OPTIMA is a ... built for life science labs in ... four different measurement principles: Fluorescence ... applications Time-Resolved Fluorescence including ...
... kit measures mitochondria intactness and detects ... potential. Features and Benefits: ... staining isolated mitochondria and for assaying ... the reagents required for the detection ...
Biology Products: